Neuraminidase 1 (NEU1) promotes proliferation and migration as a diagnostic and prognostic biomarker of hepatocellular carcinoma
Metrics: PDF 2177 views | HTML 2127 views | ?
Guojun Hou1,*, Gang Liu2,3,*, Yuan Yang1,*, Yixue Li2, Shengxian Yuan1, Linghao Zhao1, Mengchao Wu4, Lei Liu3, Weiping Zhou1
1The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China
2Key Laboratory of Systems Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China
3Institute of Biomedical Sciences, Fudan University, Shanghai, China
4The Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, China
*These authors have contributed equally to this work
Weiping Zhou, email: [email protected]
Lei Liu, email: [email protected]
Keywords: neuraminidase 1, hepatocellular carcinoma, prognosis, migration, proliferation
Received: May 18, 2016 Accepted: August 13, 2016 Published: September 01, 2016
Hepatocellular carcinoma (HCC) is among the most malignant cancers worldwide, lacking biomarkers for subtyping and the reliable prognostication. Herein, we report a novel biomarker, NEU1 (neuraminidase 1), is up-regulated in most samples of HCC. The diagnostic value of NEU1 was evaluated by ROC, and the AUC (area under curve) reached 0.87 and 0.96 in two independent datasets, respectively. The survival differences of HCC patients with high or low expression of NEU1 were statistically significant, and a significant correlation between NEU1 expression and clinical information including stage, differentiation, AFP and embolus were observed. NEU1 expression, at both the mRNA and protein levels, were also higher in the portal vein tumor thrombus than tumor tissues. We also measured the proliferation and migration ability of two HCC cell lines following NEU1 interference and over-expression. Migration and proliferation rate were increased in NEU1 high expression groups. Moreover, gene expression studies identified pathways significantly associated with NEU1 expression. Among them, all the genes involved in spliceosomepathway were up regulated in NEU1-high group. In summary, our work identified NEU1 as a novel biomarker for both diagnosis and prognosis in HCC, and one of the most altered pathway of NEU1 is spliceosome.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.